Table 4 Impact of testing on patient concerns for their family members.

From: Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients

Impact of test results and post-test counseling/discussions with physicians

No. (%) of patients

Significant differences

Significant p values

Overall [n = 476]

Positive [n = 54]

Negative [n = 213]

VUS-only [n = 209]

Reduced my concerns a lot

127 (26.7)

5 (9.3)

77 (36.2)

45 (21.5)

Neg > Pos

0.0009

Reduced my concerns somewhat

80 (16.8)

5 (9.3)

42 (19.7)

33 (15.8)

Neg > VUS

0.0009

Increased my concerns somewhat

35 (7.4)

20 (37.0)

4 (1.9)

11 (5.3)

Pos > Neg

0.0009

Increased my concerns a lot

8 (1.7)

5 (9.3)

1 (0.5)

2 (1.0)

Pos > VUS

0.0009

No change

227 (47.7)

19 (35.2)

87 (40.8)

121 (57.9)

NS

NS

  1. To account for multiple comparisons, a Bonferroni correction was applied to the p values.
  2. VUS variant of uncertain significance.
Back to article page